Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC

Genentech’s phase III IMmotion151 study met its co-primary endpoint ofprogression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death in people whose disease expressed the PD-L1 (PD-L1 expression ≥1 percent) protein compared with sunitinib for the first-line treatment of people who have advanced or metastatic renal cell carcinoma.